 Joshua Wisell
Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 8 | 2019 | 762 | 2.110 |
Why?
| | Sporotrichosis | 2 | 2018 | 4 | 1.350 |
Why?
| | Immunocompromised Host | 3 | 2019 | 200 | 1.320 |
Why?
| | Diagnostic Errors | 2 | 2016 | 162 | 0.920 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 2018 | 224 | 0.740 |
Why?
| | Plasmablastic Lymphoma | 1 | 2019 | 6 | 0.700 |
Why?
| | Itraconazole | 1 | 2018 | 7 | 0.680 |
Why?
| | Dermatomycoses | 1 | 2018 | 9 | 0.670 |
Why?
| | Paget Disease, Extramammary | 1 | 2018 | 3 | 0.660 |
Why?
| | Opportunistic Infections | 1 | 2018 | 44 | 0.660 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 94 | 0.630 |
Why?
| | Carcinoma, Merkel Cell | 1 | 2017 | 16 | 0.620 |
Why?
| | Transplant Recipients | 1 | 2019 | 148 | 0.610 |
Why?
| | Pathology, Surgical | 1 | 2016 | 8 | 0.580 |
Why?
| | Frozen Sections | 1 | 2016 | 24 | 0.570 |
Why?
| | Melanoma | 4 | 2017 | 664 | 0.560 |
Why?
| | Neurodermatitis | 1 | 2015 | 1 | 0.540 |
Why?
| | Foot Dermatoses | 1 | 2015 | 5 | 0.540 |
Why?
| | Acanthosis Nigricans | 1 | 2015 | 6 | 0.540 |
Why?
| | Hyperpigmentation | 1 | 2015 | 11 | 0.530 |
Why?
| | Minocycline | 1 | 2015 | 28 | 0.530 |
Why?
| | Acne Vulgaris | 1 | 2015 | 20 | 0.530 |
Why?
| | Granular Cell Tumor | 1 | 2014 | 7 | 0.480 |
Why?
| | SOXE Transcription Factors | 1 | 2014 | 17 | 0.480 |
Why?
| | Quality Assurance, Health Care | 1 | 2016 | 325 | 0.480 |
Why?
| | Biomarkers, Tumor | 3 | 2017 | 1059 | 0.470 |
Why?
| | Scalp | 1 | 2013 | 29 | 0.460 |
Why?
| | Decidua | 1 | 2012 | 27 | 0.430 |
Why?
| | Hemangioendothelioma, Epithelioid | 1 | 2011 | 5 | 0.420 |
Why?
| | Cicatrix | 1 | 2012 | 53 | 0.420 |
Why?
| | Skin Ulcer | 1 | 2011 | 15 | 0.420 |
Why?
| | Endometriosis | 1 | 2012 | 42 | 0.420 |
Why?
| | Cesarean Section | 1 | 2012 | 165 | 0.380 |
Why?
| | Skin Diseases | 1 | 2012 | 125 | 0.380 |
Why?
| | Head and Neck Neoplasms | 1 | 2013 | 471 | 0.320 |
Why?
| | Biopsy | 4 | 2021 | 1079 | 0.300 |
Why?
| | Graft vs Host Disease | 3 | 2023 | 216 | 0.290 |
Why?
| | Glycogen | 1 | 2006 | 59 | 0.290 |
Why?
| | Immunohistochemistry | 3 | 2018 | 1691 | 0.280 |
Why?
| | Brain Neoplasms | 1 | 2014 | 1023 | 0.270 |
Why?
| | Exome | 2 | 2017 | 220 | 0.260 |
Why?
| | Hepatocytes | 1 | 2006 | 205 | 0.260 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1390 | 0.260 |
Why?
| | HIV Infections | 1 | 2018 | 2461 | 0.240 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 10 | 0.230 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2017 | 202 | 0.230 |
Why?
| | Humans | 26 | 2023 | 119032 | 0.220 |
Why?
| | Male | 15 | 2021 | 57818 | 0.220 |
Why?
| | Skin | 3 | 2021 | 657 | 0.210 |
Why?
| | Adult | 11 | 2021 | 31525 | 0.210 |
Why?
| | Proto-Oncogene Proteins | 2 | 2017 | 618 | 0.200 |
Why?
| | Skin Diseases, Vascular | 1 | 2021 | 8 | 0.200 |
Why?
| | Mastocytosis, Cutaneous | 1 | 2021 | 5 | 0.200 |
Why?
| | Embolism | 1 | 2021 | 43 | 0.190 |
Why?
| | Mastocytosis | 1 | 2021 | 12 | 0.190 |
Why?
| | Mutation | 3 | 2017 | 3457 | 0.190 |
Why?
| | Vasculitis | 1 | 2021 | 75 | 0.190 |
Why?
| | Biopsy, Needle | 2 | 2018 | 190 | 0.180 |
Why?
| | Exanthema | 2 | 2018 | 77 | 0.170 |
Why?
| | Pregnancy Complications | 1 | 2023 | 448 | 0.170 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2013 | 610 | 0.160 |
Why?
| | Paint | 1 | 2017 | 8 | 0.160 |
Why?
| | Neurofibromin 1 | 1 | 2017 | 22 | 0.150 |
Why?
| | Carcinoma | 1 | 2019 | 204 | 0.150 |
Why?
| | Armadillo Domain Proteins | 1 | 2017 | 5 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2017 | 64 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2017 | 25 | 0.150 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 50 | 0.150 |
Why?
| | Intraoperative Period | 1 | 2016 | 55 | 0.140 |
Why?
| | Mucous Membrane | 1 | 2017 | 113 | 0.140 |
Why?
| | Necrosis | 2 | 2021 | 231 | 0.140 |
Why?
| | Genes, erbB-1 | 1 | 2016 | 18 | 0.140 |
Why?
| | Phosphoproteins | 1 | 2017 | 308 | 0.130 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 181 | 0.130 |
Why?
| | Middle Aged | 8 | 2019 | 27627 | 0.120 |
Why?
| | 4-Nitroquinoline-1-oxide | 1 | 2013 | 5 | 0.120 |
Why?
| | Aged | 6 | 2019 | 19661 | 0.120 |
Why?
| | Tongue Neoplasms | 1 | 2013 | 21 | 0.120 |
Why?
| | Stilbenes | 1 | 2013 | 35 | 0.120 |
Why?
| | Oximes | 1 | 2013 | 18 | 0.120 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 793 | 0.120 |
Why?
| | Smad4 Protein | 1 | 2013 | 37 | 0.120 |
Why?
| | Prognosis | 2 | 2018 | 3443 | 0.120 |
Why?
| | Grape Seed Extract | 1 | 2013 | 41 | 0.110 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2017 | 407 | 0.110 |
Why?
| | Carcinogens | 1 | 2013 | 108 | 0.110 |
Why?
| | Anticarcinogenic Agents | 1 | 2013 | 68 | 0.110 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2013 | 71 | 0.110 |
Why?
| | Diagnosis, Differential | 2 | 2015 | 1384 | 0.110 |
Why?
| | Pyrimidinones | 1 | 2013 | 86 | 0.110 |
Why?
| | Neoplastic Stem Cells | 2 | 2013 | 336 | 0.110 |
Why?
| | ras Proteins | 1 | 2013 | 141 | 0.110 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2012 | 38 | 0.110 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2013 | 179 | 0.110 |
Why?
| | Pyridones | 1 | 2013 | 119 | 0.110 |
Why?
| | Imidazoles | 1 | 2013 | 232 | 0.100 |
Why?
| | Mitotic Index | 1 | 2011 | 27 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2016 | 648 | 0.100 |
Why?
| | Treatment Outcome | 2 | 2018 | 9346 | 0.100 |
Why?
| | Carcinoma in Situ | 1 | 2011 | 45 | 0.100 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 544 | 0.100 |
Why?
| | Carcinoma, Lobular | 1 | 2011 | 56 | 0.090 |
Why?
| | Female | 12 | 2023 | 61588 | 0.090 |
Why?
| | Antigens, CD20 | 1 | 2010 | 28 | 0.090 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 325 | 0.090 |
Why?
| | Bone Marrow Transplantation | 2 | 2010 | 244 | 0.090 |
Why?
| | Receptor, ErbB-2 | 1 | 2012 | 320 | 0.090 |
Why?
| | Breast Neoplasms | 2 | 2012 | 1965 | 0.090 |
Why?
| | Estrogens | 1 | 2012 | 329 | 0.090 |
Why?
| | Receptors, Estrogen | 1 | 2012 | 387 | 0.090 |
Why?
| | Adenocarcinoma | 1 | 2016 | 812 | 0.090 |
Why?
| | Risk Assessment | 1 | 2018 | 3057 | 0.090 |
Why?
| | Vipoma | 1 | 2008 | 1 | 0.080 |
Why?
| | Hypertension, Portal | 1 | 2008 | 67 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 1868 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2010 | 462 | 0.070 |
Why?
| | Inclusion Bodies | 1 | 2006 | 25 | 0.070 |
Why?
| | Hepatitis B, Chronic | 1 | 2006 | 18 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1517 | 0.070 |
Why?
| | Apoptosis | 2 | 2013 | 2484 | 0.070 |
Why?
| | Cytoplasm | 1 | 2006 | 269 | 0.070 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2017 | 452 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2220 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2010 | 1346 | 0.050 |
Why?
| | Carcinogenesis | 2 | 2013 | 182 | 0.050 |
Why?
| | Purpura | 1 | 2021 | 12 | 0.050 |
Why?
| | Tablets | 1 | 2021 | 35 | 0.050 |
Why?
| | Foreign-Body Reaction | 1 | 2021 | 23 | 0.050 |
Why?
| | Fasciotomy | 1 | 2021 | 20 | 0.050 |
Why?
| | Pancreatic Neoplasms | 1 | 2008 | 734 | 0.050 |
Why?
| | Tumor Cells, Cultured | 2 | 2013 | 874 | 0.050 |
Why?
| | Injections, Intravenous | 1 | 2021 | 210 | 0.050 |
Why?
| | Triazines | 1 | 2021 | 39 | 0.050 |
Why?
| | Fingers | 1 | 2021 | 83 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2021 | 287 | 0.050 |
Why?
| | Foreign Bodies | 1 | 2021 | 98 | 0.050 |
Why?
| | Pyrroles | 1 | 2021 | 191 | 0.040 |
Why?
| | Retrospective Studies | 1 | 2016 | 12990 | 0.040 |
Why?
| | Fetus | 1 | 2023 | 690 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2023 | 540 | 0.040 |
Why?
| | Pyrazoles | 1 | 2021 | 363 | 0.040 |
Why?
| | Patient Compliance | 1 | 2021 | 537 | 0.040 |
Why?
| | Lung Transplantation | 1 | 2019 | 263 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2017 | 141 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2017 | 6562 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 167 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2016 | 381 | 0.030 |
Why?
| | Side-Population Cells | 1 | 2013 | 10 | 0.030 |
Why?
| | alpha Catenin | 1 | 2013 | 14 | 0.030 |
Why?
| | In Situ Nick-End Labeling | 1 | 2013 | 124 | 0.030 |
Why?
| | Cell Dedifferentiation | 1 | 2013 | 30 | 0.030 |
Why?
| | Tongue | 1 | 2013 | 73 | 0.030 |
Why?
| | Sequence Deletion | 1 | 2013 | 171 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2013 | 245 | 0.030 |
Why?
| | CD24 Antigen | 1 | 2012 | 21 | 0.030 |
Why?
| | Substance-Related Disorders | 1 | 2021 | 971 | 0.030 |
Why?
| | Breast Neoplasms, Male | 1 | 2012 | 31 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 237 | 0.030 |
Why?
| | Child, Preschool | 1 | 2006 | 9493 | 0.030 |
Why?
| | Mice | 3 | 2013 | 15528 | 0.030 |
Why?
| | Hyaluronan Receptors | 1 | 2012 | 93 | 0.030 |
Why?
| | Precision Medicine | 1 | 2016 | 363 | 0.030 |
Why?
| | Computational Biology | 1 | 2016 | 588 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2013 | 176 | 0.030 |
Why?
| | Mice, Nude | 1 | 2013 | 663 | 0.030 |
Why?
| | Mice, SCID | 1 | 2012 | 333 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2013 | 300 | 0.030 |
Why?
| | RNA Interference | 1 | 2013 | 460 | 0.030 |
Why?
| | Tamoxifen | 1 | 2012 | 198 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2016 | 671 | 0.030 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2012 | 143 | 0.030 |
Why?
| | Tumor Burden | 1 | 2012 | 275 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 5694 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2012 | 481 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2012 | 239 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 574 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 770 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 740 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3173 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2010 | 134 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2010 | 217 | 0.020 |
Why?
| | Adrenalectomy | 1 | 2008 | 79 | 0.020 |
Why?
| | Splenectomy | 1 | 2008 | 57 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2025 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4596 | 0.020 |
Why?
| | Acantholysis | 1 | 2007 | 2 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1167 | 0.020 |
Why?
| | Pancreaticoduodenectomy | 1 | 2008 | 128 | 0.020 |
Why?
| | Animals | 3 | 2013 | 33399 | 0.020 |
Why?
| | Child | 1 | 2006 | 19137 | 0.020 |
Why?
| | MicroRNAs | 1 | 2013 | 637 | 0.020 |
Why?
| | Pancreatectomy | 1 | 2008 | 165 | 0.020 |
Why?
| | Transcriptome | 1 | 2012 | 756 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2007 | 415 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2013 | 2275 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2010 | 770 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 4914 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2010 | 2661 | 0.010 |
Why?
| | Young Adult | 1 | 2017 | 10799 | 0.010 |
Why?
| | Biomarkers | 1 | 2010 | 3590 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 4713 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2008 | 2436 | 0.010 |
Why?
|
|
Wisell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|